Ansuvimab

安舒韦单抗

Report date: 2022/03/18 10:20:32

Base Information

Drug NameAnsuvimab
Drug Alias NameAnsuvimab-zyklEbangaVRC-EBOMAB092-00-ABMAb114MAb-114
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEnvelope glycoprotein inhibitors
TargetsEnvelope glycoprotein
Therapy Area/IndicationsHemorrhagic Fever, Ebola
Global Approved IndicationsHemorrhagic Fever, Ebola
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/12/21
Country/TerritoryUnited StatesCongo, The Democratic Republic of the
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)National Institute of Health, Islamabad
China Registration ClassN/A

Develop Information

Active CompaniesRidgeback Biotherapeutics LpEmergent Biosolutions IncBiomedical Advanced Research And Development Authority
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsHemorrhagic Fever, Ebola
Inactive IndicationsN/A

Other Information

ATC CodeD06BB
Related LinksN/A